Dalbavancin (Xydalba®) is recommended as an option for restricted use within NHS Wales. Dalbavancin (Xydalba®) should be restricted for use in the following circumstances within its licensed indication for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults:

• as a second-line treatment of ABSSSI; or
• when methicillin-resistant Staphylococcus aureus (MRSA) infection is suspected; or 
• on the advice of local microbiologists or infectious disease specialists; and
• the patient is at first hospitalised due to ABSSSI and needs intravenous antibiotics but is allowed early discharge as they don’t need further inpatient treatment.

Dalbavancin (Xydalba®) is not recommended for use within NHS Wales outside of these circumstances.